Korean Circ J.  1986 Sep;16(3):379-387. 10.4070/kcj.1986.16.3.379.

Clinical Study on the Antiplatelet Aggregation Effect of Ticlopidine Hydrochloride(Ticlid(R))

• Oh BH
• Lee MM
• Park YB
• Choi YS
• Seo JD
• Lee YW

• KMID: 1668797
• DOI: http://doi.org/10.4070/kcj.1986.16.3.379

Abstract

The antiplatelet aggregation effect of ticlopidine was studied in 22 cases of coronary artery disease(CAD) and 17 cases of control by obseving changes of plarma beta-thromboglobulin(beta-TG) and platelet factor 4(PF-4) before and after administration of ticlopidine 500mmg daily for 2 weeks. 1) Compared with the controls, CAD patients had significantly greater plasm levels of beta-TG(52.6+/-32.7ng/ml. mean +/-SD vs. 91.0+/-52.0, P<0.05) and PF-4(17.5+/-12.8 ng/ml vs. 32.9+/-24.5, P<0.05). 2) In controls, plasma levels of beta-TG and PF-4 didn't change significantly after taking ticlopidine. 3) In CAD patients, plasma levels of beta-TG (91.0+/-52.0ng/ml vs. 53.9+/-20.0, P<0.05) and PF-4(32.9+/-24.5ng/ml vs. 18.8 +/-11.9(P<0.05) decreased significantly after ticlopidine. 4) The side effects were observed in 2 cases such as mild indigestion and urticaria.

MeSH Terms

Blood Platelets
Coronary Vessels
Dyspepsia
Humans
Plasma
Ticlopidine*
Urticaria
Ticlopidine